Daily Sepsis Research Analysis
Three impactful sepsis studies span engineering, mechanistic biology, and clinical stewardship. A twisted-integrated fiber sensor enabled real-time pH and glucose monitoring and improved survival in septic mice. Epitranscriptomic control via HNRNPC driving NF-κB/CD80 signaling explains tubular injury in sepsis-induced AKI, and a 331-episode cohort supports short-course antibiotics for uncomplicated enterococcal bacteremia without worse outcomes.
Summary
Three impactful sepsis studies span engineering, mechanistic biology, and clinical stewardship. A twisted-integrated fiber sensor enabled real-time pH and glucose monitoring and improved survival in septic mice. Epitranscriptomic control via HNRNPC driving NF-κB/CD80 signaling explains tubular injury in sepsis-induced AKI, and a 331-episode cohort supports short-course antibiotics for uncomplicated enterococcal bacteremia without worse outcomes.
Research Themes
- Real-time metabolic monitoring and bioelectronic therapy in sepsis
- Epitranscriptomic mechanisms driving organ injury in sepsis
- Antimicrobial stewardship: optimizing antibiotic duration in bacteremia
Selected Articles
1. A Twisted-Integrated Multifunctional Fiber Sensor for Real-Time Metabolic Monitoring and Management of Sepsis.
This study introduces a twisted-integrated fiber sensor that simultaneously measures pH and glucose with high sensitivity and stability in sepsis models. PGF-guided metabolic management improved survival and reduced organ damage in septic mice by disrupting the acidosis–glucose dysregulation cycle.
Impact: It pioneers a minimally invasive, multimodal monitoring platform that not only tracks sepsis metabolism in real time but also guides interventions that improve survival in vivo.
Clinical Implications: Suggests a translational path for continuous metabolic monitoring (pH and glucose) to guide individualized interventions in sepsis; could inform ICU decision support and closed-loop metabolic therapy.
Key Findings
- A twisted-integrated fiber sensor (PGFs) simultaneously monitored pH and glucose with rapid response and high sensitivity, enhancing bioelectrode interface stability and biocompatibility.
- Long-term in vivo monitoring generated temporal metabolic profiles of sepsis.
- PGF-guided metabolic management significantly improved survival and reduced organ injury in septic mice by breaking the acidosis–glucose dysregulation cycle and dampening inflammation.
Methodological Strengths
- Innovative multimodal sensing with integrated reference electrodes enabling stable, high-fidelity real-time measurements
- In vivo longitudinal monitoring with survival outcomes and mechanistic validation
Limitations
- Preclinical animal model; human feasibility, safety, and efficacy remain untested
- Invasiveness and durability in clinical ICU settings require evaluation
Future Directions: First-in-human feasibility studies to assess safety, signal fidelity, and clinical utility; integration with closed-loop metabolic control and validation across diverse sepsis phenotypes.
Sepsis-induced systemic metabolic dysregulation involves complex interactions between acid-base imbalance and glucose metabolism abnormalities. Traditional metabolic monitoring methods, which rely on intermittent blood sampling, lack sufficient spatiotemporal resolution and fail to capture the dynamic pathological changes in detail. To address this, we present a minimally invasive multifunctional fiber sensor (PGFs) with a twisted integration structure for real-time, simultaneous monitoring of pH and glucose concentrations in sepsis. PGFs integrate pH and glucose fiber sensors along with their reference electrodes through a twisted design, offering excellent flexibility, rapid response, and high sensitivity. Additionally, the twisted structure enhances the stability of the bioelectrode-organic interface and improves biocompatibility. Long-term monitoring using PGFs in a sepsis animal model allowed us to construct a temporal metabolic profile of sepsis. Furthermore, metabolic management with PGFs significantly improved the survival rate of septic mice and alleviated sepsis-induced organ damage. Mechanistic studies revealed that PGFs-based combined intervention effectively disrupted the vicious cycle between acidosis and glucose dysregulation, reducing sepsis-induced inflammation and immune responses, improving the metabolic microenvironment, and restoring energy homeostasis. In conclusion, this study provides a platform for metabolic monitoring and management in sepsis using PGFs, offering valuable insights for clinical therapeutic strategies.
2. HNRNPC-Mediated m6A Epitranscriptomics Drives CD80-Dependent Tubular Dysfunction in Sepsis-Induced AKI.
The study delineates an HNRNPC–NF-κB–CD80 axis in sepsis-induced AKI, where HNRNPC promotes NF-κB (via m6A regulation) and increases CD80 transcription, driving tubular apoptosis and cytoskeletal injury. In vivo validation underscores HNRNPC and CD80 as candidate therapeutic targets.
Impact: It identifies a coherent epitranscriptomic mechanism linking m6A regulation to NF-κB-driven CD80 expression and tubular injury, offering actionable molecular targets for S-AKI.
Clinical Implications: Targeting HNRNPC, NF-κB m6A regulation, or CD80 signaling may attenuate tubular apoptosis in S-AKI; translational studies and drug development are warranted.
Key Findings
- HNRNPC upregulation induced tubular apoptosis and cytoskeletal deformation via m6A-dependent regulation of NF-κB mRNA.
- NF-κB acted as a transcription factor to promote CD80 expression; CD80 was essential for HNRNPC-induced tubular injury.
- In vivo experiments validated the HNRNPC–NF-κB–CD80 relationships and their significance in sepsis-induced AKI.
Methodological Strengths
- Comprehensive multimodal assays (dot blot m6A, RNA-seq, luciferase, EMSA, ChIP, MeRIP-qPCR) supporting mechanistic causality
- In vivo validation corroborating in vitro mechanistic findings
Limitations
- Preclinical study without human tissue validation or clinical correlates
- Therapeutic modulation of the pathway was not tested in interventional models
Future Directions: Validate the HNRNPC–NF-κB–CD80 axis in human S-AKI biospecimens; develop small-molecule or RNA-based modulators and test efficacy in sepsis models with clinically relevant endpoints.
Sepsis-associated acute kidney injury (S-AKI) is a critical condition characterized by renal tubular epithelial cell apoptosis and abnormal cytoskeleton. This study aims to investigate the role of the m6A modification-dependent protein HNRNPC in regulating renal cell apoptosis and cytoskeleton in S-AKI. Dot blot analysis was employed to assess the total m6A levels. Cell viability, flow cytometry, and fluorescent phalloidin staining were used to evaluate the role of HNRNPC in CD80-dependent apoptosis and cytoskeletal remodeling. RNA sequencing and subsequent data analysis highlighted the involvement of the NF-κB signaling pathway. Luciferase reporter assays and Western blot were used to establish that HNRNPC transcriptionally promotes CD80 expression. Bioinformatics, EMSA, and ChIP assays further confirmed the role of NF-κB in regulating CD80. Additionally, MeRIP-qPCR and RNA m6A quantification demonstrated that HNRNPC facilitates apoptosis through m6A-dependent regulation of NF-κB. Induction of HNRNPC to a higher level can induce apoptosis and cytoskeletal deformation in renal tubular cells. Meanwhile, CD80 was essential for HNRNPC-induced tubular injury. Further experiments showed that HNRNPC regulated NF-κB mRNA dependent on m6A modification. Moreover, NF-κB acted as a transcription factor to promote CD80 expression. In vivo experiments further verified the relationships between HNRNPC, NF-κB, and CD80 and demonstrated the significance of HNRNPC in CD80-associated apoptosis. This study elucidates the molecular mechanisms underlying the pathogenesis of S-AKI and highlights the potential of HNRNPC and CD80 as therapeutic targets to reduce renal damage in S-AKI.
3. Short course of antimicrobial treatment for uncomplicated enterococcal bacteremia.
In 331 episodes of uncomplicated enterococcal bacteremia, short-course antibiotics (4–10 days) had the same 120-day composite outcome rate (23%) as longer courses (11–18 days). Malignancy, immunosuppression, cirrhosis, and sepsis/septic shock predicted worse outcomes, whereas short duration was not associated with harm.
Impact: Supports shorter antibiotic durations for uncomplicated enterococcal bacteremia, a stewardship-relevant question with direct practice implications.
Clinical Implications: For uncomplicated enterococcal bacteremia, a 4–10-day antibiotic course appears reasonable, while recognizing higher-risk subgroups (malignancy, immunosuppression, cirrhosis, sepsis/shock) that may warrant closer follow-up.
Key Findings
- Across 331 episodes, the 120-day composite outcome occurred in 23% with no difference between short (4–10 days) and long (11–18 days) therapy (23% vs 23%; P=1.000).
- Short-course therapy was not associated with increased risk in multivariable Cox regression (aHR 1.03, 95% CI 0.65–1.62).
- Malignancy (aHR 2.00), immunosuppression (aHR 1.78), cirrhosis (aHR 2.53), and sepsis/septic shock (aHR 2.48) independently predicted adverse outcomes.
Methodological Strengths
- Relatively large single-center cohort with clearly defined uncomplicated bacteremia
- Multivariable Cox regression addressing key confounders with 120-day follow-up
Limitations
- Retrospective, single-center design limits causal inference and generalizability
- Non-randomized treatment duration decisions may introduce residual confounding
Future Directions: Prospective, ideally randomized trials to confirm non-inferiority of short-course therapy and to stratify duration by risk profiles.
PURPOSE: Duration of treatment for uncomplicated enterococcal bacteremia is unknown. This study aims to evaluate the clinical outcomes of patients treated with short courses (4-10 days) compared to those receiving longer regimens (11-18 days). METHODS: This retrospective study was conducted at the Lausanne University Hospital, Switzerland (January 2015-June 2024) and included adult patients with uncomplicated enterococcal bacteremia. Primary outcome was a composite of mortality, recurrence of bacteremia by the same enterococcal species and development of bone and joint infection within 120 days. RESULTS: During the study period, 331 episodes of uncomplicated enterococcal bacteremia were included. The median duration of antimicrobial treatment was 12 days (interquartile range: 8-15); 138 (42%) and 193 (58%) episodes received a short (4-10 days) and long (11-18 days) duration of antimicrobial treatment, respectively. The primary endpoint was observed in 77 (23%) episodes; 120-day mortality was 21% (69 episodes), recurrence of bacteremia was 4% (12 episodes), and bone and joint infection was 0.6% (2 episodes). No difference in primary endpoint was observed between episodes receiving short and long courses of antimicrobial treatment (23% versus 23%; P = 1.000). The Cox multivariable regression model found that malignancy (aHR 2.00, 95% CI 1.24-3.22), immunosuppression (1.78, 1.09-2.90), cirrhosis (2.53, 1.42-4.51), and sepsis or septic shock (2.48, 1.52-4.03) were associated with primary endpoint; a short course of antimicrobial treatment was not associated with primary endpoint (1.03, 0.65-1.62). CONCLUSION: Among uncomplicated enterococcal bacteremia giving a short duration of antimicrobial treatment is reasonable.